{"organizations": [], "uuid": "5849630d354f85d14fc8037f4c40bd6ab070658a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lilly-receives-additional-fda-appr/brief-lilly-receives-additional-fda-approval-for-verzenio-idUSL8N1QG7FT", "country": "US", "domain_rank": 408, "title": "BRIEF-Lilly Receives Additional FDA Approval For Verzenio​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T01:20:00.000+02:00", "replies_count": 0, "uuid": "5849630d354f85d14fc8037f4c40bd6ab070658a"}, "author": "", "url": "https://www.reuters.com/article/brief-lilly-receives-additional-fda-appr/brief-lilly-receives-additional-fda-approval-for-verzenio-idUSL8N1QG7FT", "ord_in_thread": 0, "title": "BRIEF-Lilly Receives Additional FDA Approval For Verzenio​", "locations": [], "entities": {"persons": [{"name": "lilly", "sentiment": "none"}], "locations": [], "organizations": [{"name": "verzenio", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "eli lilly and co", "sentiment": "none"}, {"name": "verzenio​ reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Eli Lilly And Co:\n* LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIO (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER\n* SAYS ‍NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER​\n* SAYS ‍RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY​\n* SAYS ‍VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-27T01:20:00.000+02:00", "crawled": "2018-02-27T01:35:57.010+02:00", "highlightTitle": ""}